Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation

Li Jiang, Lu-Nan Yan

Li Jiang, Lu-Nan Yan, Department of Liver and Vascular Surgery, Liver Transplantation Center, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China

Author contributions: Jiang L and Yan LN contributed equally to this paper.

Correspondence to: Lu-Nan Yan, MD, PhD, Department of Liver and Vascular Surgery, Liver Transplantation Center, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China. yanlunanhx@163.com

Telephone: +86-28-85422867 Fax: +86-28-85422469

Received: March 14, 2010 Revised: April 12, 2010

Accepted: April 19, 2010

Published online: May 28, 2010

Abstract

Hepatitis B virus (HBV)-related liver disease is the leading indication for liver transplantation (LT) in Asia, especially in China. With the introduction of hepatitis B immunoglobulin (HBIG) and oral antiviral drugs, the recurrent HBV infection rate after LT has been evidently reduced. However, complete eradication of recurrent HBV infection after LT is almost impossible. Recurrent graft infection may lead to rapid disease progression and is a frequent cause of death within the first year after LT. At present, the availability of new oral medications, especially nucleoside or nucleotide analogues such as adefovir dipivoxil, entecavir and tenofovir disoproxil fumarate, further strengthens our ability to treat recurrent HBV infection after LT. Moreover, since combined treatment with HBIG and antiviral agents after liver re-transplantation may play an important role in improving the prognosis of recurrent HBV infection, irreversible graft dysfunction secondary to recurrent HBV infection in spite of oral medications should no longer be considered an absolute contraindication for liver re-transplantation. Published reviews focusing on the therapeutic strategies for recurrent HBV infection after LT are very limited. In this article, the current therapeutic strategies for recurrent HBV infection after LT and evolving new trends are reviewed to guide clinical doctors to choose an optimal treatment plan in different clinical settings.

© 2010 Baishideng. All rights reserved.

Key words: Therapy; Hepatitis B virus; Recurrent hepatitis B virus infection; Antiviral drugs; Liver transplantation

Peer reviewer: Dr. Thamara Perera, Senior Transplant Fellow, The Liver Transplant Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, United Kingdom

Jiang L, Yan LN. Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. World J Gastroenterol 2010; 16(20): 2468-2475 Available from: URL: http://www.wjgnet.com/1007-9327/full/v16/i20/2468.htm DOI: http://dx.doi.org/10.3748/wjg.v16.i20.2468

INTRODUCTION

Hepatitis B virus (HBV)-related liver disease accounts for approximately 5%-10% of all liver diseases after liver transplantsations (LT) performed each year in the United States and is the leading indication for LT in Asia[1,2]. It was reported that the recurrent HBV infection rate after LT is as high as 80%-100% without any prophylaxis[3,4]. The recurrent HBV infection rate has been decreased from 90% to approximately 30%-40% since the introduction of hepatitis B immunoglobulin (HBIG)[5,6]. With the advances in oral antiviral drugs, combined treatment with HBIG and lamivudine (LAM), recommended by many centers, has achieved encouraging outcomes, with the recurrent HBV infection rate reduced to less than 10% during a follow-up period of 1-2 years[7-11]. However, combined treatment with HBIG and LAM cannot control recurrent HBV infection. Recurrent graft infection may lead to rapid disease progression and is a frequent cause of death within the first year after LT[12].
Furthermore, the incidence of acquiring de novo HBV infection after LT in patients who are negative for hepatitis B surface antigen (HBsAg) is 1.7%-3.5%, and patients with de novo HBV infection are also at a risk for severe progressive liver injury\(^\text{[13-15]}\). The aggressive clinical course is probably due to stimulation of viral replication and direct cytoxicity of HBV under immunosuppressive therapy. Therefore, suppression of HBV replication is paramount to prevent disease progression in the transplanted liver.

Unfortunately, almost all published reviews focusing on the prophylactic strategies against recurrent HBV infection after LT, have drawn less prominence to the treatment of recurrent HBV infection in recipients after LT. Published reviews, focusing on the therapeutic strategies against recurrent HBV infection after LT, are very limited, and almost all of them are already nearly obsolete. In the following, the current therapeutic strategies for recurrent HBV infection after LT and evolving new trends are reviewed.

### INTERFERON

In the pre-LAM era, interferon \(\alpha\) is a common therapeutic option for patients with recurrent HBV infection after LT. However, with the advent of LAM, it has not been used as a first-line treatment drug. Patients using interferon \(\alpha\) have a lower efficacy and a higher risk of precipitating allograft rejection than those using LAM\(^\text{[16,17]}\). Furthermore, treatment of recurrent HBV infection after LT with interferon \(\alpha\) can lead to side effects such as neutopenia.

### LAM

LAM can potentially inhibit HBV replication by competitively suppressing the reverse transcriptase and termination of proviral DNA chain extension, and has been used in treatment of recurrent HBV infection, with an excellent safety profile in both compensated and decompensated cirrhotic patients. The use of LAM in treatment of recurrent HBV infection after LT has shown promising results as is shown in a multicenter North American study on 52 patients with chronic hepatitis B after LT, demonstrating that use of LAM for 52 wk can result in loss of serum HBV DNA in 69%, undetectable hepatitis B e antigen (HBeAg) in 31%, undetectable HBsAg in 6%, normalization of serum alanine transaminase (ALT) levels in 71% of patients, respectively\(^\text{[18]}\). The results from other studies\(^\text{[18-27]}\) are summarized in Table 1, showing that LAM can suppress HBV DNA to undetectable levels in 32.5%-100%, anti-HBeAg seroconversion in 4.2%-100%, and anti-HBsAg seroconversion in 0%-83.3% of patients, respectively, after 4.6-36 mo of treatment. Notably, use of LAM in treatment of de novo HBV infection or acute recurrent HBV infection of the graft after LT tends to effectively suppress HBV DNA, and converse serum anti-HBeAg and anti-HBsAg.

However, the major factor limiting the use of LAM in treatment of graft HBV infection after LT is the development of mutations in tyrosine-methionine-aspartate-aspartate (YMDD) motif of the HBV DNA polymerase gene, which confers resistance to LAM. In non-immunosuppressed patients, the LAM resistance rate is 15%-20%\(^\text{[28]}\). LAM resistance can be detected in 45% of immunosuppressed patients within the first year of treatment\(^\text{[29,30]}\). It has been reported that YMDD mutation occurs in 26.9%, 27.3%, 29.4% and 62.5% of patients with recurrent HBV infection\(^\text{[18,20,22,24]}\) after 12, 15, 21 and 36 mo of treatment with LAM, respectively. It has also been reported that YMDD mutation occurs in patients with de novo HBV infection after LT, in 0%, 0% and 14.3% of patients with recurrent HBV infection\(^\text{[31,32,27]}\) after 4.6, 11 and 24.5 mo of treatment with LAM, respectively. One possible explanation for it is the short-term use of LAM in patients with de novo HBV infection and low HBV-DNA levels at the acute phase of de novo HBV reactivation.

Available data from the literature regarding the outcomes secondary to YMDD mutation are controversial. Perrillo et al\(^\text{[33]}\) reported that the YMDD mutant virus is not consistently associated with hepatic disease progression, whereas elevated serum ALT can be frequently observed at the time when serum HBV DNA becomes detectable again, and the mean ALT values after breakthrough often remain below the pretreatment values. However, McCaughan et al\(^\text{[34]}\) reported that patients infected with procure mutant strains of HBV develop drug resistance or liver failure after 11 mo of rescue therapy with LAM. Mutimer et al\(^\text{[35]}\) also demonstrated that LAM-resistant phenotype can cause severe graft damage. Hence, long-term, randomized, blinded, and controlled clinical trials are needed to further observe the clinical outcomes following LAM resistance.

In summary, LAM therapy results in not only a loss of viral replication markers in serum and an improved hepatic biochemical profile, but also improvement or stabilization in liver histology. However, LAM resistance and its possible accompanying clinical deterioration have limited its long-term use in treatment of recurrent HBV infection after LT.

### Adefovir dipivoxil

Adefovir dipivoxil (ADV), a nucleotide analog that selectively inhibits viral polymerases and reverse transcriptase, is effective against both negative and positive HBeAg\(^\text{[36-38]}\). Furthermore, it has been shown that ADV has an excellent activity against wild-type as well as LAM-resistant HBV strains\(^\text{[39,40]}\), suggesting that ADV contributes to the development of LAM-resistant mutants and de novo LAM-resistant HBV infection after LT. Schiff et al\(^\text{[41]}\) in a landmark multicenter study showed that PCR DNA levels are decreased with a 1-year survival rate of 93%, undetectable serum HBV DNA, normal serum ALT, albumin, bilirubin and prothrombin time in 34%, 49%, 76%, 75% and 20% of patients, respectively, after 24 and 48 wk of treatment with ADV. Four years later, Schiff et al\(^\text{[42]}\) further showed that the serum HBV DNA...
levels are undetectable in 40%, 65% and 78% of patients with recurrent HBV infection and LAM resistance 48, 96 and 114 wk after ADV treatment (10 mg, once a day), respectively, as well as loss or seroconversion of HBeAg in 31% and 11% of patients by week 48, and in 58% and 34% of patients by week 96. Liver function and other parameters after treatment with ADV are shown in Figure 1. Other studies\[44-48\] are summarized in Table 2. Toniutto et al\[30\] reported that ADV plus LAM can achieve favorable outcomes of HBeAg seroconversion and undetectable HBV DNA in patients with de novo graft HBV infection and LAM resistance.

Mildly elevated serum creatinine level may occur after treatment with ADV, especially with calcineurin inhibitors, but only a small number of patients require dose adjustment, and even discontinuance. However, renal function should be regularly monitored, with dose adjustments based on renal function, as necessary.

In short, ADV is a safe and effective treatment option for recurrent HBV infection, especially as a salvage treatment for recurrent HBV infection due to LAM resistance.

### Table 1 Use of LAM in treatment of recurrent HBV graft infection after LT

| Author (Ref.) | n | Pre-treatment | Treatment duration (mo), mean (range) | LAM dosage (mg/d) | Post-treatment |
|---------------|---|---------------|--------------------------------------|-------------------|---------------|
|               |   | HBV DNA+ (%)  | HBeAg+ (%)                           |                   |               |
| Ben-Ari et al\[26\] | 8 | 100           | 62.5                                  | 36 (24-50)        | 100           |
| Umeda et al\[26\]   | 6 | 100           | NA                                    | 4.6 (7-11)        | 100           |
| Castells et al\[26\] | 7 | 100           | 85.7                                  | 24.5 (12-49)      | 100           |
| Fontana et al\[25\] | 33| 94            | 75                                    | 21 (4-36)         | NA            |
| Andreone et al\[26\] | 11| 100           | 18.2                                  | 17 (8-27)         | 100           |
| Perrelli et al\[26\] | 52| 90.4          | 86.5                                  | 12                | 100           |
| Nery et al\[25\]    | 11| 90.9          | NA                                    | 15 (13-21)        | NA            |
| Fischer et al\[25\] | 12| 100           | NA                                    | 10.5 (5-43)       | 100-150       |
| Rays et al\[26\]    | 41| 100           | NA                                    | 12-36             | 150           |
| Malkan et al\[26\]  | 4 | 100           | 75                                    | 11 (4-28)         | 100-150       |

|                   |   | HBV DNA negative following treatment (%) | HBeAg seroconversion (%) | HBeAg seroconversion (%) | Development of LAM resistant mutants (%) |
|-------------------|---|----------------------------------------|-------------------------|-------------------------|----------------------------------------|
| Ben-Ari et al\[26\] | 8 | 32.5                                   | 20                      | 0                       | 62.5                                   |
| Umeda et al\[26\]   | 6 | NA                                     | NA                      | 83.3                    | 0                                      |
| Castells et al\[26\] | 7 | 71.4                                   | 50                      | 14.3                    | 143                                    |
| Fontana et al\[25\] | 33| 72                                     | 4.2                     | 0                       | 29.4                                   |
| Andreone et al\[26\] | 11| 100                                    | 100                     | 9.1                     | 27.3                                   |
| Perrelli et al\[26\] | 52| 68.1                                   | 11.1                    | 3.8                     | 26.9                                   |
| Nery et al\[25\]    | 11| 90                                     | NA                      | NA                      | 27.3                                   |
| Fischer et al\[25\] | 12| 83.3                                   | NA                      | NA                      | NA                                     |
| Rays et al\[26\]    | 41| 75.6                                   | NA                      | NA                      | 24.4                                   |
| Malkan et al\[26\]  | 4 | 100                                    | 25                      | 0                       | 0                                      |

\[1\] All patients had de novo HBV infection after LT; \[2\] This study reported treatment of acute recurrent graft HBV infection. NA: Not available; HBV: Hepatitis B virus; LT: Liver transplantation; HBeAg: Hepatitis B e antigen; HBeAg: Hepatitis B surface antigen; LAM: Lamivudine.

### Table 2 Use of ADV in treatment of recurrent graft infection after LT

| Author (Ref.) | n | Pre-treatment | Treatment duration (mo), mean (range) | ADV dosage (mg/d) | Concurrent LAM use | Post-treatment | Concurrent LAM use |
|---------------|---|---------------|--------------------------------------|-------------------|--------------------|----------------|-------------------|
|               |   | HBV DNA+ (%)  | HBeAg+ (%)                           |                   |                    |                |                   |
| Akyildiz et al\[46\] | 11 | 81.8             | 9.1                                  | 18 (6-48)         | 10                 | Yes            | 77.8              |
| Limquico et al\[46\] | 7  | 100            | 71.4                                  | 35 (22-48)        | 10                 | Yes            | 28.6              |
| Bárceca et al\[46\] | 42 | 100            | 71.4                                  | 21.5 (12-31)      | 10                 | No             | 64                |
| Herreros de Tejada | 7  | 100            | 71.4                                  | 11                | 10                 | Yes\[2\]       | 42.9              |
| Echanojáuregui et al\[46\] | 12 | 100            | 77.8                                  | 30 (6-48)         | 10                 | No             | 0                 |

|                   |   | HBV DNA negative following treatment (%) | HBeAg seroconversion (%) | ALT normalization (%) | Development of ADV mutants |
|-------------------|---|----------------------------------------|-------------------------|-----------------------|---------------------------|
| Akyildiz et al\[46\] | 11| 77.8                                   | 11.1                    | 81.8                  | None                      |
| Limquico et al\[46\] | 7 | 28.6                                   | 20                      | 86                    | None                      |
| Bárceca et al\[46\] | 42| 64                                     | 20                      | 70.5                  | None                      |
| Herreros de Tejada | 7  | 42.9                                   | 20                      | NA                    | None                      |
| Echanojáuregui et al\[46\] | 12 | 0                                      | 57.1                    | NA                    | None                      |

\[1\] LAM was changed to ADV in 5 patients and ADV was added to LAM in the other 2 patients. ADV: Adefovir dipivoxil.

**Entecavir**

Entecavir (ETV), a very potent anti-HBV selective guanosine analogue, approved by the US FDA in 2005, can be used in treatment of chronic HBV infection. Unfortunately, few reports are available on ETV in treatment of recurrent HBV infection. Most data concerning its efficacy and safety are obtained from patients with no LT. It was reported that 0.5 mg of ETV or 100 mg of LAM, once daily for 48 wk, can improve the histology...
in 72% and 62% of patients, respectively, with serum HBV DNA undetectable in 67% and 36% of patients, respectively, and normal ALT in 68% and 60% of patients, respectively, and no evidence of viral resistance to ETV\(^{[56]}\). It has been shown that 0.5 mg of ETV or 100 mg of LAM, once daily for 48 wk, can also achieve favorable outcomes in patients with nucleoside-naive HBcAg-negative chronic hepatitis B\(^{[56]}\), suggesting that the histologic, virologic and biochemical improvement rates are significantly higher after ETV treatment than after LAM treatment, in patients with nucleoside-naive HBcAg-positive or -negative chronic hepatitis B, with no evidence of viral resistance to ETV, which is consistent with the findings in other studies\(^{[53,54]}\). The mean decrease in serum HBV DNA after 2, 4, 8, 12, 24 and 48 wk of ETV and ADV treatment in patients is shown in Figure 2. A recent study demonstrated that ETV therapy is safe and efficient for recipients with ADV-resistant HBV infection\(^{[54]}\).

ETV resistance is associated with the LAM-resistance substitutions M204V/I and L180M in combination with an additional substitution at residues T184, S202 or M250 in the reverse-transcriptase region of HBV polymerase\(^{[53]}\). In other words, ETV is associated with a high genetic barrier to resistance requiring multiple mutations for resistance development. In nucleoside-naive patients, the probability of developing resistance to ETV remains consistently low (< 1.2%) even after 96 wk of treatment\(^{[56]}\). By contrast, ETV gives rise to ETV-resistant mutants in patients with LAM resistance. The rate of ETV resistance in LAM-resistant patients 4 years after treatment of may reach 35%\(^{[57]}\), which is due to a particular selection mode of ETV strains that follows a 2-step process, with the selection of primary resistance mutations at position M204V/I (which are also resistant to LAM) followed by the addition of secondary resistance mutations on the same viral genomes\(^{[58]}\). Once these secondary substitutions occur, high-level resistance to ETV occurs. Therefore, the high probability of resistance to long-term ETV in LAM resistant patients with no LT suggests that ETV is not a good choice for LAM-resistant patients after LT, although ETV has been tried in some LAM resistant patients after LT\(^{[54]}\). However, ETV can be used in non-LAM resistant patients, due to its great potency, high genetic barrier and absence of nephrotoxicity. More data are urgently needed to confirm the safety and efficacy of ETV after LT.

**Figure 2** Mean serum hepatitis B virus (HBV) DNA level in patients after entecavir (ETV) and adefovir (ADV) treatment\(^{[56]}\).

**Figure 3** Viral suppression, ALT normalization and hepatitis B surface antigen (HBsAg) loss in hepatitis B e antigen (HBcAg)-positive (A) and HBcAg-negative (B) patients after tenofovir disoproxil fumarate (TDF) and adefovir treatment\(^{[49]}\). HBV DNA level of less than 400 copies/mL.

**Tenofovir disoproxil fumarate**

Tenofovir disoproxil fumarate (TDF), a nucleotide analogue, inhibits viral polymerases by direct binding to DNA or by terminating the DNA chain due to the absence of a requisite 3' hydroxyl on the tenofovir molecule\(^{[59]}\). In 2001, TDF was licensed for HIV therapy as a potent inhibitor of HIV replication. Subsequently, it has been proved to be a potent and selective anti-HBV agent in vitro\(^{[60]}\). Several clinical studies have currently confirmed the efficacy of TDF in suppressing HBV replication. Marcellin et al\(^{[61]}\) showed that the antiviral efficacy of TDF is higher than that of ADV with no resistance mutation in patients with HBcAg-negative or HBcAg-positive chronic HBV infection. Detail data regarding viral suppression, liver function improvement, and serologic response are shown in Figure 3. It has been shown that TDF has an excellent antiviral activity against both wild-type and LAM-resistant HBV both in vitro and in vivo\(^{[62,63]}\). Furthermore, TDF shows a stronger antiviral effect than ADV on LAM-resistant HBV\(^{[64,65]}\). Hann et al\(^{[66]}\) reported that the mean level of HBV DNA is 1.5 ± 1.0 log10 copies/mL and 4.3 ± 2.2 log10 copies/mL, respectively, in patients with LAM.
Resistance after treatment with TDF and ADV. A recent study demonstrated that TDF plus LAM can safely and markedly suppress HBV replication in patients with or without resistance to ADV[7].

The daily TDF dose (300 mg) has been approved as a standard dose for controlling HBV infection. To reduce the cost of therapy, a low TDF dose (75 mg) can be used to control HBV viremia in patients with chronic HBeAg-negative hepatitis B, which can more effectively inhibit HBV replication than ADV at the standard dose[8]. However, further studies are needed to determine its efficacy and safety in a larger number of HBeAg-positive subjects.

Only 2 reports are available on TDF-related mutations conferring resistance to TDF[69,70]. Transfection experiments showed that rtA194T mutation alone can result in a 7.6-fold decrease in susceptibility to TDF; but rtA194T mutation in combination with ADV-resistant mutations can lead to a more than 10-fold decrease in susceptibility to TDF[70]. However, TDF susceptibility to rtA194T mutation is not consistent with its clinical significance. Since 2005, ADV-resistance mutations (rtN236T, rtA194T, rtA181V) have not caused a significant change in TDF susceptibility[71,72]. Only one study is available on the application of TDF in treatment of recurrent HBV infection after LT[73]. Although TDF can significantly decrease LAM-resistant HBV variant replication after LT, further studies are needed to determine its efficacy and safety profile with a long follow-up time and a large cohort of patients.

RETRANSPLANTATION

With the advent of new antiviral drugs such as ADV, ETV and TDF, satisfactory outcomes can be achieved in patients with recurrent HBV infection by suppressing viral replication. However, some patients with irreversible graft dysfunction secondary to recurrent HBV infection still need a second LT to replace the primary graft[74,75]. To date, second LT accounts for 5%-22% of all LTs in adults[76]. Samuel et al[77] reported that recurrent graft HBV infection is the direct cause of death in patients with hepatitis B after a second LT. Crippin et al[78] showed that the mortality rate of patients with recurrent HBV infection is 95% after a second LT, which is consistent with the findings in other studies[79,80].

Ishitani et al[81] showed that long-term HBIG therapy can continuously maintain a serum anti-HBs level > 500 IU/L and prevent recurrent HBV infection in 86% of patients after a second LT. Roche et al[82] reported that prophylactic intravenous ganciclovir can maintain an anti-HBs titre greater than 500 IU/L, with a satisfactory prognosis of all patients after a second LT. Lo et al[83] demonstrated that combined injection of ADV, LAM and HBIG can maintain an anti-HBs titre greater than 100 IU/L in patients with LAM-resistant HBV mutants after a second LT.

In summary, recurrent HBV infection after a primary LT should no longer be considered an absolute contraindication for a second LT. Combined HBIG and antiviral agents may play an important role in improving the prognosis of patients with recurrent HBV infection after a second LT. Further randomized study is needed to definitely confirm it.

CONCLUSION

The emergence of new oral medications, especially nucleoside or nucleotide analogues such as ADV, ETV and TDF, further increases our ability to treat recurrent HBV infection after LT. By recognizing the efficacies and features of such drugs, various therapeutic strategies, according to different clinical settings, have been recommended to control the recurrent graft infection after LT (Table 3). For the de novo or wild-type HBV infection after LT, long-term use of LAM is limited by the high risk of developing mutations in YMDD motif. Hence, ADV is the first choice in this setting, if needing long-term administration. For the LAM-resistant HBV infection after LT, ADV, administered in combination with LAM or as a monotherapy, appears to be safe and effective in this setting. Theoretically, “add therapy” may minimize the risk of resistance, but needs long-term, randomized, blinded, controlled clinical trials to further confirm it. In addition, ETV is not a good choice for LAM-resistant patients after LT because of its high probability of resistance in patients with LAM resistance without LT. ETV therapy for ADV-resistant HBV infection after LT is safe and efficient in this setting. Additionally, combined TDF and LAM therapy may be an alternative approach based on its favorable therapeutic effects in patients with out LT. However, no or few data are available on the efficacy of ETV and TDF in patients after LT. Further clinical trials are needed to evaluate their efficacy and safety in this special setting. Second LT is the only rescue procedure for patients with irreversible graft dysfunction secondary to recurrent HBV infection. Since combined HBIG and antiviral agents may play an important role in improving the prognosis of patients with recurrent HBV infection after LT, recurrent HBV infection after a primary LT should no longer be considered an absolute contraindication for a second LT.

---

Table 3 Summary of recommended therapeutic strategies for recurrent HBV infection after LT

| Clinical setting | Recommended first line therapies | Recommended second line therapies |
|------------------|----------------------------------|----------------------------------|
| De novo HBV infection, wild-type | LAM for short-term therapy | ETV, TDF |
| HBV infection | ADV resistant | long-term therapy |
| LAM resistance | ADV, ADV + LAM | TDF |
| ADV resistance | ETV | TDF + LAM |
| Irreversible graft dysfunction | SLT | SLT: Second liver transplantation. |

ETV: Entecavir; TDF: Tenofovir disoproxil fumarate; SLT: Second liver transplantation.
REFERENCES

1 Seaberg EC, Belle SH, Beringer KC, Schivins JL, Dette KM. Liver transplantation in the United States from 1987-1998: updated results from the Prit-UNOS Liver Transplant Registry. Clin Transpl 1998; 17-27

2 Lo CM, Fan ST, Liu CL, Lai CL, Wong J. Prophylaxis and treatment of recurrent hepatitis B after liver transplantation. Transplantation 2003; 75: S41-S44

3 Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfecction following liver transplantation: a concise review. Hepatology 2000; 32: 1189-1195

4 Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klemmnaier J, Manns MP, Boker KHW. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfecion after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfecion. J Hepatol 2001; 34: 895-902

5 McGorry RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC, Caldwell SH, Fruett TL. Improved outcome of orthotopic liver transplantation for chronic hepatitis C cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 1358-1364

6 Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, Ascher NL, Wright TL. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24: 1327-1333

7 Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, Gentilcore E, Piantino P, Barbui AM, David JL, Negri F, Rizzetto M, Sgaglione L. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34: 903-910

8 Markowitz JS, Martin P, Conrad AJ, Markmann JF, Sevw P, Yersits H, Goss JA, Schmid P, Pakrasi A, Artinian L, Murray NG, Imagawa DK, Holt C, Goldstein I, Strobl R, Busuttil RW. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-589

9 Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, Dawson S, Goldstein L, Yersits H, Farmer DG, Ghobrial RM, Busuttil RW, Martin P. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6: 741-748

10 Steinmüller T, Seeboher D, Nayaes N, Mülher AR, Settmacher U, Jonas S, Neuhaus R, Berg T, Hofp U, Neuhaus P. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35: 1528-1535

11 Rosenau J, Tillmann HL, Bahr MJ, Trautwein C, Beoker KH, Nashan B, Klemmnaier J, Manns MP. Successful hepatitis B reinfecion prophylaxis with lamivudine and hepatitis B immune globulin in patients with positive HBV-DNA at time of liver transplantation. Transplant Proc 2001; 33: 3637-3638

12 Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: 619-626

13 Roche B, Samuel D, Gigou M, Ferray C, Virot V, Schint M, David MF, Aruland A, Bismuth A, Remyes M, Bismuth H. Ne novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol 1997; 26: 517-526

14 Fabia R, Levy MF, Crippen J, Tillyery W, Netto GJ, Aguannu J, Dysert P, Goldstein RM, Husberg BS, Gonwa TA, Klintmalm GB. De novo hepatitis B infection after liver transplantation: source of disease, incidence, and impact. Liver Transpl Surg 1998; 4: 119-127

15 Chazouillères O, Mamish D, Kim M, Carey K, Ferrell L, Roberts JP, Ascher NL, Wright TL. “Occult” hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994; 343: 142-146

16 Terrault NA, Holland CC, Ferrell L, Hahn JA, Lake JR, Roberts JP, Ascher NL, Wright TL. Interferon alfa for recurrent hepatitis B infection after liver transplantation. Liver Transpl Surg 1996; 2: 132-138

17 Wright HI, Galavera JS, Van Thiel DH. Preliminary experience with alpha-2b-interferon therapy of viral hepatitis in liver allograft recipients. Transplantation 1992; 53: 121-124

18 Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, Caldwell S, Schiff E, Gish R, Villeneuve JP, Farr G, Anschuetz G, Crowther L, Brown N. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology 1999; 29: 1581-1586

19 Umeda M, Marusawa H, Ueda M, Takada Y, Egawa H, Uemoto S, Chiba T. Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation. Am J Transplant 2006; 6: 2680-2685

20 Ben-Ari Z, Mor E, Shapira Z, Tur-Kaspa R. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transpl 2001; 7: 113-117

21 Castells L, Vargas Y, Rodríguez F, Allende H, Buti M, Sánchez-Avila JF, Jardi R, Margarit C, Pumarola T, Esteban R, Guardia J. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transpl 2002; 8: 892-900

22 Fontana RJ, Hann HW, Wright T, Everson G, Baker A, Schiff ER, Riely C, Anschuetz G, Riker-Hopkins M, Brown N. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl 2001; 7: 504-510

23 Andreone P, Caraceni P, Grazi GL, Belli L, Milandri GL, Ercolani G, Jovine E, D’Errico A, Dal Monte PR, Ideo G, Forti D, Mazzotti A, Cavallari A, Bernardi M. Lamivudine treatment for acute hepatitis B after liver transplantation. J Hepatol 1998; 29: 985-989

24 Nery JR, Weyplder D, Rodríguez M, Ruiz P, Schiff E, Tazaks AG. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 1998; 65: 1615-1621

25 Fischer L, Sterneck M, Zollner B, Bogers X. Lamivudine improves the prognosis of patients with hepatitis B after liver transplantation. Transplant Proc 2000; 32: 2128-2130

26 Rayes N, Seeboher D, Hofp U, Neuhaus R, Naumann U, Bechstein WO, Zöllner B, Rogiers X. Lamivudine in the long-term treatment of hepatitis B infection after liver transplantation. Transplant Proc 2000; 32: 741-748

27 Steinmüller T, Seeboher D, Neyaes N, Müller AR, Settmacher U, Jonas S, Neuhaus R, Berg T, Hofp U, Neuhaus P. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. J Hepatol 2001; 35: 1528-1535

28 Sánchez-Avila JF, Jardí R, Margarit C, Pumarola T, Esteban R, Guardia J. Clinical impact and efficacy of lamivudine therapy for hepatitis B after liver transplantation. Am J Transplant 2003; 3: 1615-1621

29 Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Wessner M, Boehme R, Condeay L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-696

30 Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000–summary of a workshop. Gastroenterology 2001; 120: 1828-1835

31 Seeboher D, Rayes N, Berg T, Neuhaus R, Müller AR, Hofp U, Bechstein WO, Neuhaus P. Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation. Transpl Int 2000; 13: 290-296

32 McCaughan GW, Spencer J, Kooray D, Bowden S, Bartholomew J, Li L, Reed J, Verran D, Chui AK, Sheil AG, Jones RM, Locarnini SA, Angus PW. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance
rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: S12-519.

32 Mutimer D, Pillay D, Shields P, Cane P, Radcliffe D, Martin B, Buchan S, Boyall L, O'Donnell K, Shaw J, Hubscher S, Elias E. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000; 46: 107-113.

33 Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzotto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgral CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-807.

34 Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgral CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816.

35 Xiong X, Flores C, Yang H, Toole J, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28: 1669-1673.

36 Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutierrez K, Lamy P, Murray A. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129-134.

37 Zeng M, Mao Y, Yao G, Wang H, Hou J, Wang Y, Ji BN, Chang CN, Barker KF. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 2006; 44: 108A-116A.

38 Toniutto P, Fumo E, Caldato M, Apollonio L, Perin A, Pirisi M. Favourable outcome of adefovir-dipivoxil treatment in acute de novo hepatitis B after liver transplantation. Transplantation 2004; 77: 472-473.

39 Peters MG, Hann Hw H, Martin P, Heathcote EJ, Buggisch P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray DF, D, Sullivan M, Kleber K, Ebrahimi R, Xiong S, Brosgral CL. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91-101.

40 Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, Moorat A, Gardner S, Woessner M, Bourne E, Brosgral CL, Schiff E. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81-90.

41 Benhamou Y, Bochet M, Thibault V, Salvez Y, Fievet MH, Vig P, Ghebremedhin G, Brosgral C, Fry J, Namini H, Katlama C, Poynard T. Safety and efficacy of adefovir dipivoxil in patients infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358: 718-723.

42 Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann HL, Samuel D, Zeuzem S, Lilly L, Rendina M, Villeneuve JP, Lama N, James C, Wulfsohn MS, Namini H, Westland C, Xiong S, Choy GS, Van Doren S, Fry J, Brosgral CL. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2005; 38: 1419-1427.

43 Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann H, Samuel D, Zeuzem S, Lilly L, Rendina M, Villeneuve JP, Lama N, James C, Wulfsohn MS, Namini H, Westland C, Xiong S, Choy GS, Van Doren S, Fry J, Brosgral CL. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2005; 38: 1419-1427.

44 Akyildiz M, Karasu Z, Zeytunlu M, Aydin U, Ozacar T, Kilic M. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. J Gastroenterol Hepatol 2007; 22: 2130-2134.

45 Limquiao JL, Wong J, Wong VW, Wong GL, Tse CH, Chan HY, Kwan KY, Lai PB, Chan HL. Lamivudine monoprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study. J Med Virol 2009; 81: 224-229.

46 Barca R, Del Campo S, Moraleda G, Casanovesa T, Pietro M, Buti M, Moreno JM, Cuervas V, Fraga E, De La Mata M, Otero A, Delgado M, Loinaz C, Barrios C, Dieguez ML, Mas A, Sousa JM, Herrera JL, Muñoz R, Avilés JF, González A, Rueda M. Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus. Transplant Proc 2005; 37: 3960-3962.

47 Herreros de Tejada Echanojáuregui A, Moreno Planas JM, Rubio González E, Portero Azorín F, López Monclus J, Revilla Negro J, Lucena de la Poza JL, Sánchez Turrisión V, Barrios Peinado C, Cuervas-Mons Martinez V. Adefovir dipivoxil therapy in liver transplant recipients with lamivudine-resistant hepatitis B virus. Transplantation Proc 2005; 37: 1507-1508.

48 Neff GW, O'Brien CB, Nery J, Shire N, Montalban-M, Ruiz P, Nery C, Safdar K, De Medina M, Tzakis AG, Schiff ER, Madariaga J. Outcomes in liver transplant recipients with hepatitis B virus: recurrence and recurrence patterns from a large transplant center over the last decade. Liver Transpl 2004; 10: 1372-1378.

49 Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, De-Hertogh D, Wilber R, Colombo R, Apelian D. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-1010.

50 Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, De-Hertogh D, Wilber R, Zink RC, Cross A, Colombo R, Fernandes L. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-1020.

51 Schiff E, Simsek H, Lee WM, Chao YC, Sette H, J, Jansen LH, Han SH, Goodman Z, Yang J, Brett-Smith H, Tamez R. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008; 103: 2776-2783.

52 Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee SD, Harris M, Yang J, Colombo R, Brett-Smith H. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-1444.

53 Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, Lesmana L, Yuen MF, Jeffers L, Sherman M, Min A, Mencarini K, Ovia L, Cross A, Wilber R, Lopez-Talavera J. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology 2009; 72-79.

54 Kamar N, Milliot O, Alric L, El Kahwaji L, Cointault O, Lavayssiere L, Saune K, Izopet J, Rostaing L. Entecavir therapy for adeverof-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008; 86: 611-614.

55 Baldick CJ, Tenney DJ, Mazzucco CE, Egggers BJ, Rose RE, Pokornowski KA, Yu CF, Colombo RJ. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology 2008; 47: 1473-1482.

56 Colombo RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Egggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006; 44: 1656-1665.

57 Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, Boron-Kaczmarska A, Martin P, Goodman Z, Colombo R, Cross A, Denisky G, Kreter B, Hindes R. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 2039-2049.
Jiang L et al. Treatment of recurrent HBV infection after liver transplantation

58 Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trépo C, Zoulim F. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007; 46: 531-538

59 De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003; 16: 569-596

60 Ying C, De Clercq E, Nicholson W, Furman P, Neys J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat 2000; 7: 161-165

61 Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tcherny K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2412-2415

62 Lada O, Benhamou Y, Cahour A, Katlama C, Peynard T, Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004; 9: 353-363

63 Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004; 2: 266-272

64 van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Schäffler M, Feucht HH, Wiedenmann B, Berg T. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44: 318-325

65 van Bömmel F, Wünsche T, Mauss S, Reinke P, Bergk A, Schürmann D, Wiedenmann B, Berg T. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40: 1421-1425

66 Han H, Chae HB, Dumn SR. Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine-resistant hepatitis B virus (HBV). Hepatol Int 2008; 2: 244-249

67 Choe WH, Kwon SY, Kim BK, Ko SY, Yeon JE, Byun KS, Kim GH, Lee CH. Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis. Liver Int 2008; 28: 814-820

68 Del Poggio P, Zaccanelli M, Oggoni M, Colombo S, Jamoletti C, Puhalo V. Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBsAg-negative hepatitis B. World J Gastroenterol 2007; 13: 4096-4099

69 Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouée-Durantel S, Villeneuve JP, Trépo C, Zoulim F. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41: 1391-1398

70 Sheldon J, Camino N, Rodés B, Bartholomeus A, Kuiper M, Tacke F, Núñez M, Mauss S, Lutz T, Klausen G, Locarnini S, Soriano V. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10: 727-734

71 Delaney WE 4th, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, Miller MD. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006; 50: 2471-2477

72 Qi X, Xiong S, Yang H, Miller M, Delaney WE 4th. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007; 12: 355-362

73 Neff GW, Nery J, Lau DT, O’Brien CB, Duncan R, Shire NJ, Ruiz P, Nery C, Montalbano M, Muslu H, Safdar K, Schiff ER, Tzakis AG, Madariaga JR. Tenofovir therapy for lamivudine resistance following liver transplantation. Ann Pharmacother 2004; 38: 1999-2004

74 Lerut J, Laterre PF, Roggen F, Mauel E, Gheerardyn R, Ciccarelli O, Donataccio M, de Ville de Goyet J, Reding R, Goffette P, Geubel A, Otte JB. Adult hepatic retransplantation. UCL experience. Acta Gastroenterol Belg 1999; 62: 261-266

75 Chen GH, Fu BS, Cai CJ, Lu MQ, Yang Y, Yi SH, Xu C, Li H, Wang GS, Zhang T. A single-center experience of retransplantation for liver transplant recipients with a failing graft. Transplant Proc 2008; 40: 1485-1487

76 Pfitzmann R, Benschmidt B, Langrehr MJ, Schumacher G, Neuhaus R, Neuhaus P. Trends and experiences in liver retransplantation over 15 years. Liver Transpl 2007; 13: 248-257

77 Samuel D, Muller R, Alexander G, Fassati I, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847

78 Crippin J, Foster B, Carlen S, Borich A, Bodenheimer H Jr. Retransplantation in hepatitis B viral carriers. Transplantation 1994; 57: 823-826

79 König V, Hopf U, Neuhaus P, Bauditz J, Schmidt CA, Blumhardt G, Bechstein WO, Neuhaus R, Lobeck H. Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation 1994; 58: 553-559

80 Roche B, Samuel D, Feray C, Majno P, Gigou M, Reyes M, Bismuth H. Re-transplantation of the liver for recurrent hepatitis B virus infection: the Paul Brousse experience. Liver Transpl Surg 1999; 5: 166-174

81 O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, Portmann B, Alexander GJ, Williams R. Hepatitis B virus infection: the Paul Brousse experience. Liver Transpl 1999; 557-563

82 Ishitani M, McCoy R, Dickson R, Caldwell S, Blackson S, McCullough C, Pruett T, Terauld N, Roberts J, Ascher N, Wright T, Lake J. Retransplantation of patients with severe post-transplant hepatitis B in the first allograft. Transplantation 1997; 64: 410-414

83 Lo CM, Cheung ST, Ng IO, Liu CL, Lai CL, Fan ST. Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance: successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin. Liver Transpl 2004; 10: 557-563

S-Editor: Wang YR  L-Editor: Wang XL  E-Editor: Zheng XM